Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01595516 · ClinicalTrials.gov registry record · Phase 4
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
A Phase 4 study of Hypertension and Prehypertension, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01595516 is a Phase 4 study of Hypertension and Prehypertension that has completed, run by University of Colorado, Boulder. The registered enrollment target is 44 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01595516, a Phase 4 study of Hypertension and Prehypertension, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER Saline
- DRUG Nebivolol
- DRUG Metoprolol
- OTHER Bradykinin
Study Locations (1)
Colorado
- UC-Boulder Clinical and Translational Research Center - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-02 |
| Est. Completion | 2017-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01595516
The ClinicalTrials.gov registry entry for NCT01595516 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01595516 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01595516 about?
NCT01595516 is a clinical study titled "Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)". The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-P...
What is the current status of trial NCT01595516?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2012-02. Estimated completion is 2017-10.
What conditions does trial NCT01595516 study?
This clinical trial studies the following conditions: Hypertension, Prehypertension.
What interventions are being tested in trial NCT01595516?
The interventions under investigation include: Placebo (DRUG), Saline (OTHER), Nebivolol (DRUG), Metoprolol (DRUG), Bradykinin (OTHER).
Who is sponsoring clinical trial NCT01595516?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01595516 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.